Relafen 750, or novel formulation of naproxen, represents a intriguing example from our biochemical pharmacy view. This mode of action, essentially involving inhibition of cyclooxygenase enzymes namely COX-1 and COX-2 – contributes to the reduction in prostaglandin creation. Considering a biochemical lens, this drug's effectiveness is closely ass